AUTHOR=Muderrisoglu Ahmet , Babaoglu Elif , Korkmaz Elif Tugce , Ongun Mert C. , Karabulut Erdem , Iskit Alper B. , Emri Salih , Babaoglu Melih O. 

TITLE=Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation

JOURNAL=Frontiers in Genetics

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.571997

DOI=10.3389/fgene.2020.571997

ISSN=1664-8021

ABSTRACT=<sec><title>Objectives</title><p>To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.</p></sec><sec><title>Methods</title><p>130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) (<italic>n</italic> = 40), bupropion (<italic>n</italic> = 47), bupropion + NRT (<italic>n</italic> = 15), and varenicline (<italic>n</italic> = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.</p></sec><sec><title>Results</title><p>Cessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline (<italic>p</italic> = 0.013). The frequency of ABCB1 <italic>1236TT-2677TT-3435TT</italic> haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; <italic>p</italic> = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 (<italic>p</italic> = 0.652, <italic>p</italic> = 0.328, respectively), or variants of CYP2B6 (<italic>p</italic> = 0.514, <italic>p</italic> = 0.779, respectively).</p></sec><sec><title>Conclusion</title><p>Genetic variants of the drug transporter ABCB1 and the <italic>1236TT-2677TT-3435TT</italic> haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.</p></sec>